Evidence map›Paper›PMID 37764196›Full record

ArticleMicroorganisms2023

Response Surface Methodology Application for Bacteriophage-Antibiotic Antibiofilm Activity Optimization.

Bartłomiej Grygorcewicz, Marta Gliźniewicz, Patrycja Olszewska, Dominika Miłek, Artur Czajkowski, Natalia Serwin, Elżbieta Cecerska-Heryć, Rafał Rakoczy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. A Predictive Computational Framework forPathogens (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bartłomiej GrygorcewiczFaculty of Pharmacy, Medical Biotechnology and Laboratory Medicine, Pomeranian Medical University, Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland.ORCID 0000-0002-0593-0069
Marta GliźniewiczFaculty of Pharmacy, Medical Biotechnology and Laboratory Medicine, Pomeranian Medical University, Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland.
Patrycja OlszewskaFaculty of Pharmacy, Medical Biotechnology and Laboratory Medicine, Pomeranian Medical University, Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland.
Dominika MiłekFaculty of Pharmacy, Medical Biotechnology and Laboratory Medicine, Pomeranian Medical University, Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland.
Artur CzajkowskiFaculty of Pharmacy, Medical Biotechnology and Laboratory Medicine, Pomeranian Medical University, Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland.
Natalia SerwinFaculty of Pharmacy, Medical Biotechnology and Laboratory Medicine, Pomeranian Medical University, Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland.ORCID 0000-0002-1769-2037
Elżbieta Cecerska-HeryćFaculty of Pharmacy, Medical Biotechnology and Laboratory Medicine, Pomeranian Medical University, Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland.ORCID 0000-0002-7313-7193
Rafał RakoczyDepartment of Chemical and Process Engineering, Faculty of Chemical Technology and Engineering, West Pomeranian University of Technology in Szczecin, Piastów Ave. 42, 71-065 Szczecin, Poland.ORCID 0000-0002-5770-926X

Funding

National Centre for Research and Development LIDER/12/0069/L-12/20/NCBR/2021
6 · The paper itself

Abstract

Phage-antibiotic combination-based protocols are presently under heightened investigation. This paradigm extends to engagements with bacterial biofilms, necessitating novel computational approaches to comprehensively characterize and optimize the outcomes achievable via these combinations. This study aimed to explore the Response Surface Methodology (RSM) in optimizing the antibiofilm activity of bacteriophage-antibiotic combinations. We employ a combination of antibiotics (gentamicin, meropenem, amikacin, ceftazidime, fosfomycin, imipenem, and colistin) alongside the bacteriophage vB_AbaP_AGC01 to combat

Indexed as

antimicrobialsbiofilmmathematical modelingphages

Identifiers

PMID37764196
PMCPMC10536537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.